Drug Stocks' Earnings To Watch On May 16: ADHD, MCRB & More
Zacks Investment Research | May 12, 2016 09:26PM ET
The Q1 earnings season is almost wrapping up with 90.2% (as of May 11) of the S&P 500 members having already reported results. Now how does the picture look like? While growth remained nonexistent, the results were not that bad with a number of companies coming out with positive surprises for both earnings as well as revenues.
However, 2016 earnings growth expectations have turned negative similar to what was seen last year. Earnings ESP of 0.00% for the first quarter thereby making it difficult to predict a beat.
Editas Medicine Inc. (NASDAQ:EDIT) is one of the leading genome editing company developing a proprietary genome editing platform based on CRISPR/Cas9 technology. The company is looking to treat patients with genetically defined diseases by correcting their disease causing genes. This Cambridge, MA-based company, which started trading from Feb 2016, has a Zacks Rank #3 which when combined with an ESP of 0.00% makes a surprise prediction difficult.
Based in Waltham, MA, Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is a development-stage biopharmaceutical company focused on the development of entinostat as a combination therapy in multiple cancer indications. Syndax started trading from March this year. The company’s Zacks Rank #3 with an ESP of 0.00% once again makes a surprise prediction difficult this quarter.
One of the leading microbiome therapeutics platform companies, Seres Therapeutics, Inc. (NASDAQ:MCRB) is a development stage company focused on the development of a novel class of biological drugs designed to treat disease by restoring the function of a dysbiotic microbiome. This Cambridge, MA-based company, which started trading from Jun 2015, has delivered disappointing performances in both its reported quarters with the company missing estimates with a negative surprise of 19.11%. The company’s Zacks Rank #3 with an ESP of 0.00% makes a surprise prediction difficult this quarter.
Grand Prairie, TX-based Neos Therapeutics, Inc.’s (NASDAQ:NEOS) Zacks Rank #2 (Buy) increases the predictive power of the ESP. However, the company’s 0.00% ESP makes a surprise prediction difficult yet again. Neos is a pharmaceutical company focused on the development, manufacturing and commercialization of products utilizing its proprietary modified-release drug delivery technology platforms. The company, which started trading from Jul 2015, reported a positive surprise of 22.97% last quarter.
Get The News You Want
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.